Griffiths trims Silence Therapeutics (SLN) stake with 1.54M ADS sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Silence Therapeutics plc 10% owner Richard Ian Griffiths reported a series of open-market sales of American Depositary Shares (ADSs) associated with his holdings. Across six transactions between June 29 and July 6, 2026, entities linked to him sold an aggregate of 1,544,374 ADSs.
The ADSs were sold indirectly through interests, including Cream Capital Limited, with Griffiths disclaiming beneficial ownership beyond his proportionate pecuniary interest. Following these transactions, he continued to report 10,281,486 ADSs held indirectly. Each ADS is immediately convertible into three ordinary shares for no consideration and has no expiration date.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Net Sell
6 txns
Insider
Griffiths Richard Ian
Role
null
Sold
1,544,374 shs ($0.00)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | American Depositary Shares | 865,112 | $0.00 | -- |
| Sale | American Depositary Shares | 50,082 | $0.00 | -- |
| Sale | American Depositary Shares | 79,180 | $0.00 | -- |
| Sale | American Depositary Shares | 50,000 | $0.00 | -- |
| Sale | American Depositary Shares | 169,928 | $0.00 | -- |
| Sale | American Depositary Shares | 330,072 | $0.00 | -- |
Holdings After Transaction:
American Depositary Shares — 10,281,486 shares (Indirect, See footnote)
Footnotes (1)
- Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Key Figures
ADSs sold: 1,544,374 ADSs
ADSs held after transactions: 10,281,486 ADSs
Number of sale transactions: 6 transactions
+1 more
4 metrics
ADSs sold
1,544,374 ADSs
Aggregate open-market sales June 29–July 6, 2026
ADSs held after transactions
10,281,486 ADSs
Indirect holdings reported following July 6, 2026 sales
Number of sale transactions
6 transactions
Open-market or private sales in the Form 4
ADS to ordinary share ratio
1 ADS = 3 ordinary shares
Each ADS immediately convertible for no consideration
Key Terms
American Depositary Shares, open-market sale, indirect ownership, beneficial ownership, +1 more
5 terms
open-market sale financial
"Each transaction is characterized as an open-market sale of ADSs."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"The ADS holdings are reported as indirect ownership through related entities."
beneficial ownership financial
"Griffiths disclaims beneficial ownership beyond his pecuniary interest."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider activity did Silence Therapeutics (SLN) report for Richard Ian Griffiths?
Silence Therapeutics reported that 10% owner Richard Ian Griffiths had entities linked to him execute six open-market sales of American Depositary Shares, totaling 1,544,374 ADSs between June 29 and July 6, 2026, according to the Form 4 filing.
How many Silence Therapeutics (SLN) ADSs were sold in the latest Form 4?
The Form 4 shows aggregate open-market sales of 1,544,374 American Depositary Shares. These sales occurred over six transactions from June 29 through July 6, 2026, and involved indirect holdings associated with Richard Ian Griffiths, including Cream Capital Limited.
How many Silence Therapeutics (SLN) ADSs does Richard Ian Griffiths report after these sales?
After the reported transactions, Richard Ian Griffiths continues to report indirect ownership of 10,281,486 American Depositary Shares. This figure represents his remaining position following the series of open-market sales disclosed in the Form 4 filing.
Were the Silence Therapeutics (SLN) insider transactions classified as open-market sales?
Yes. Each transaction in the Form 4 is coded with “S” and described as an open-market or private sale. The filing characterizes all six reportable trades as open-market sales of American Depositary Shares linked to Richard Ian Griffiths’ indirect holdings.